Kiora Pharmaceuticals Inc
KPRX | $3.43 4.2K
|
Manufacturing
(0.0% 1d) (-13.9% 1m) (455.0% 1y) (0.0% 2d) (0.0% 3d) (2.1% 7d) (-45.51% volume)
Earnings Calendar: 2023-03-23
Market Cap: $ 6,583,096
https://eyegatepharma.com
Sec Filling | Patents | 14 employees
(United States) EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
msa
add to watch list email alert is off
Press-releases
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Published: 2023-03-30 (Crawled : 17:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
| Email alert
Add to watchlist
kio-301 meeting study
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Published: 2023-03-23 (Crawled : 14:20) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: 0.0%
H: 1.1%
C: -9.37%
update pharmaceuticals financial
Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
Published: 2023-03-10 (Crawled : 16:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: 0.39%
H: 0.0%
C: 0.0%
pharmaceuticals meeting
Groundbreaking clinical trial underway to improve vision in individuals with advanced Retinitis Pigmentosa (RP)
Published: 2023-02-14 (Crawled : 00:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: -8.09%
H: 0.0%
C: 0.0%
trial
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: 64.94%
H: 0.0%
C: 0.0%
kio-101 treatment pharmaceuticals drug ocular approval presentation study
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
Published: 2023-01-09 (Crawled : 17:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
| Email alert
Add to watchlist
pharmaceuticals
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Published: 2023-01-03 (Crawled : 17:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
| Email alert
Add to watchlist
kio-201 pharmaceuticals expected trial
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
Published: 2022-11-18 (Crawled : 15:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: -35.01%
H: 0.0%
C: 0.0%
pharmaceuticals
Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa
Published: 2022-11-17 (Crawled : 15:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: 5.83%
H: 14.53%
C: -8.72%
kio-301 pharmaceuticals study phase 2b
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Published: 2022-11-09 (Crawled : 17:00) - biospace.com/
KPRX | $3.43 4.2K
|
Manufacturing
|
| O: -1.92%
H: 2.45%
C: -3.92%
kio-301 pharmaceuticals trial financial phase 1
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 88% | 12% |
Top 10 Gainers
ENSC | $5.18 815.36% 150K
|
Health Technology
SAFE | $29.515 286.83% 380K
|
Finance
YMAB | $5.65 71.73% 12M
|
Health Technology
INPX | $0.5279 42.68% 22M
|
Technology Services
EAST | $0.35 42.28% 110K
|
Commercial Services
IONQ | $6.59 29.72% 23M
|
Professional, Scientific, and T...
PALI | $3.4 28.3% 25M
|
Manufacturing
BCLI | $3.16 26.4% 1.1M
|
Health Technology
SOUN | $2.47 25.38% 12M
|
FOXO | $0.459 24.05% 1.4M
|
Last 48 Hours Insiders Buying
RCG P 409 | $2.85 0%
|
Miscellaneous
|
14:20
PATI P 695 | $8.03 1.65% 6K
|
Transportation
|
14:10
AREN P 89989 | $4.39 13.44% 57K
|
Information
|
13:30
RILY P 993557 | $28.83 1.55% 72K
|
Finance
|
13:20
UTI P 112390 | $7.3 3.55% 91K
|
Commercial Services
|
23:50
XAIR P 10000 | $6.755 2.97% 320K
|
Technology Services
|
22:50
PED P 263931 | $1.01 6.32% 640K
|
Industrial Services
|
22:50
ALOT P 123 | $14.365 3.27% 4.5K
|
Electronic Technology
|
22:10
RFIL P 2227 | $4.21 12K
|
Electronic Technology
|
21:50
DICE P 195997 | $29.47 2.79% 120K
|
|
21:10
HPKEW 4 | $14.0 0%
|
Industrial Services
|
23:50